Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03684447 · ClinicalTrials.gov registry record · Phase 2
Neural and Antidepressant Effects of Propofol
A Phase 2 study of Treatment-Resistant Depression, sponsored by University of Utah.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT03684447 is a Phase 2 study of Treatment-Resistant Depression that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 48 participants, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03684447, a Phase 2 study of Treatment-Resistant Depression, is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.
Conditions Studied
Interventions
- DRUG Propofol
Study Locations (1)
Utah
- University Neuropsychiatric Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2019-04-21 |
| Est. Completion | 2024-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03684447
The ClinicalTrials.gov registry entry for NCT03684447 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 373-participant average among 54 other Treatment-Resistant Depression trials with a reported enrollment target (87% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Treatment-Resistant Depression appearing as the primary indexed condition, and to 1 intervention - of which Propofol is the first listed.
NCT03684447 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT03684447 about?
NCT03684447 is a clinical study titled "Neural and Antidepressant Effects of Propofol". This study will compare the antidepressant effects of propofol at two different doses while measuring potential treatment-related biomarkers.
What is the current status of trial NCT03684447?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2019-04-21. Estimated completion is 2024-07.
What conditions does trial NCT03684447 study?
This clinical trial studies the following conditions: Treatment-Resistant Depression.
What interventions are being tested in trial NCT03684447?
The interventions under investigation include: Propofol (DRUG).
Who is sponsoring clinical trial NCT03684447?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03684447 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Treatment-Resistant Depression
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)
RECRUITING · Phase 2
-
Psilocybin rTMS for Treatment Resistant Depression
RECRUITING · Phase 2
-
Antidepressant Effects of Nitrous Oxide
RECRUITING · Phase 2
-
Mindfulness Engaged Neurostimulation for Depression
RECRUITING · Phase 2
-
Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression
ACTIVE NOT RECRUITING · Phase 2
-
An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD)
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.